Author:
Maddali Madhavi,Kulkarni Uday Prakash,Ravindra Niveditha,Jajodia Ekta,Arunachalam Arun Kumar,Suresh Hemamalini,Venkatraman Arvind,George Biju,Mathews Vikram,Balasubramanian Poonkuzhali
Funder
Department of Biotechnology, Government of India
Publisher
Springer Science and Business Media LLC
Subject
Hematology,General Medicine
Reference19 articles.
1. Szuber N, Mudireddy M, Nicolosi M, Penna D, Vallapureddy RR, Lasho TL, Finke C, Begna KH, Elliott MA, Hook CC, Wolanskyj AP, Patnaik MM, Hanson CA, Ketterling RP, Sirhan S, Pardanani A, Gangat N, Busque L, Tefferi A (2019 Apr 1) 3023 Mayo Clinic patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease subgroups. Mayo Clin Proc 94(4):599–610
2. Iurlo A, Cattaneo D, Gianelli U (2019) Blast transformation in myeloproliferative neoplasms: risk factors, biological findings, and targeted therapeutic options. Int J Mol Sci 13:20(8)
3. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR, Cancer Genome Project (2005 Mar 19) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365(9464):1054–1061
4. Vainchenker W, Kralovics R (2017) Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 129(6):667–679
5. Nangalia J, Green AR (2017) Myeloproliferative neoplasms: from origins to outcomes. Blood 130(23):2475–2483
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献